Treatment Strategy for Organ Fibrosis Targeting TGF-β and Smad Signaling
| Project/Area Number |
16590636
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
INAGAKI Yutaka Tokai University, School of Medicine, Associate Professor, 医学部, 助教授 (80193548)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IKEDA Kazuo Osaka City University, Graduate School of Medicine, Associate Professor, 大学院・医学研究科, 助教授 (80275247)
WATANABE Tetsu Tokai University, School of Medicine, Associate Professor, 医学部, 助教授 (10129744)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2005: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2004: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | Organ fibrosis / Hepatic fibrogenesis / Gene transfer / TGF-β / Smad / Collagen / Transcriptional regulation |
|---|
| Research Abstract |
Background & Aims : TGF-β and its intracellular mediators, Smad proteins, play important roles in stimulating collagen gene transcription, and thus could be the targets for treating organ fibrosis. However, intervention of the TGF-β/Smad signal affects physiological signal transduction as well, and may cause serious adverse effects upon clinical application. We have attempted to suppress liver fibrosis by expressing a TGF-β/Smad antagonist selectively in collagen-producing cells only in the fibrotic liver. Methods : Recombinant adenoviruses expressing either GFP or a TGF-β/Smad signal repressor, YB-1, were injected to the mice untreated or treated with carbon tetrachloride (CCl_4). GFP fluorescence was analyzed under a confocal laser-scanning microscopy. Anti-fibrotic effects of YB-1 overexpression were examined by luciferase assays and histological examination using transgenic reporter mice. Results : When using the CAG expression unit as a control, GFP was strongly expressed in a large number of hepatocytes in both normal and CCl_4-treated liver. In contrast, GFP expression driven by a tissue-specific enhancer of the mouse α2(I) collagen gene (COL1A2) was detected in activated hepatic stellate cells in CCl_4-induced fibrotic liver, but not in untreated normal liver. There was no GFP fluorescence observed in any other organs when using the COL1A2 enhancer. Adenovirus-mediated YB-1 expression under the control of the COL1A2 enhancer significantly decreased COL1A2 promoter activity following CCl_4 injection and subsequently suppressed the progression of liver fibrosis. Conclusions : These results validate a new concept of the therapy for hepatic fibrosis to achieve cell type-specific gene expression only in the fibrotic liver with little damage to other organs.
|
Report
(3 results)
Research Products
(39 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] リウマチ病セミナー2005
Author(s)
稲垣 豊
Total Pages
286
Publisher
永井書店
Description
「研究成果報告書概要(和文)」より
Related Report
-
-
-
-
-
-
